Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Ovarian Neoplasms

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 70 articles:
HTML format



Single Articles


    January 2021
  1. SATPATHY S, Patra A, Hussain MD, Kazi M, et al
    A fraction of Pueraria tuberosa extract, rich in antioxidant compounds, alleviates ovariectomized-induced osteoporosis in rats and inhibits growth of breast and ovarian cancer cells.
    PLoS One. 2021;16:e0240068.
    PubMed     Abstract available


  2. MOUSTAFA D, Elwahed MRA, Elsaid HH, Parvin JD, et al
    Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
    PLoS One. 2021;16:e0235025.
    PubMed     Abstract available


  3. YUK JS, Lee B, Kim K, Kim MH, et al
    Incidence and risk of venous thromboembolism according to primary treatment in women with ovarian cancer: A retrospective cohort study.
    PLoS One. 2021;16:e0250723.
    PubMed     Abstract available


  4. ZHANG R, Yang X, Roque DM, Li C, et al
    A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin.
    PLoS One. 2021;16:e0240145.
    PubMed     Abstract available


  5. ZHANG L, Hu C, Huang Z, Li Z, et al
    In Silico screening of circulating tumor DNA, circulating microRNAs, and long non-coding RNAs as diagnostic molecular biomarkers in ovarian cancer: A comprehensive meta-analysis.
    PLoS One. 2021;16:e0250717.
    PubMed     Abstract available


  6. TOKUNAGA H, Iida K, Hozawa A, Ogishima S, et al
    Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2).
    PLoS One. 2021;16:e0236907.
    PubMed     Abstract available


  7. PRAHM KP, Hogdall CK, Karlsen MA, Christensen IJ, et al
    MicroRNA characteristics in epithelial ovarian cancer.
    PLoS One. 2021;16:e0252401.
    PubMed     Abstract available


  8. WALSH CS, Kamrava M, Rogatko A, Kim S, et al
    Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer.
    PLoS One. 2021;16:e0252665.
    PubMed     Abstract available


  9. OYAMA Y, Shigeta S, Tokunaga H, Tsuji K, et al
    CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents.
    PLoS One. 2021;16:e0251079.
    PubMed     Abstract available


  10. GUI T, Yao C, Jia B, Shen K, et al
    Identification and analysis of genes associated with epithelial ovarian cancer by integrated bioinformatics methods.
    PLoS One. 2021;16:e0253136.
    PubMed     Abstract available


  11. LOPACINSKA-JORGENSEN J, Oliveira DVNP, Wayne Novotny G, Hogdall CK, et al
    Integrated microRNA and mRNA signatures associated with overall survival in epithelial ovarian cancer.
    PLoS One. 2021;16:e0255142.
    PubMed     Abstract available


  12. PARIS EA, Bahr JM, Bitterman P, Basu S, et al
    Incidence of malignant transformation in the oviductal fimbria in laying hens, a preclinical model of spontaneous ovarian cancer.
    PLoS One. 2021;16:e0255007.
    PubMed     Abstract available


  13. WANG H, Ye F, Zhou C, Cheng Q, et al
    High expression of ENPP1 in high-grade serous ovarian carcinoma predicts poor prognosis and as a molecular therapy target.
    PLoS One. 2021;16:e0245733.
    PubMed     Abstract available


  14. ALKHARUSI A, AlMuslahi A, AlBalushi N, AlAjmi R, et al
    Connections between prolactin and ovarian cancer.
    PLoS One. 2021;16:e0255701.
    PubMed     Abstract available


  15. CIRILLO PDR, Margiotti K, Fabiani M, Barros-Filho MC, et al
    Multi-analytical test based on serum miRNAs and proteins quantification for ovarian cancer early detection.
    PLoS One. 2021;16:e0255804.
    PubMed     Abstract available


  16. STEFANOU DT, Bamias A, Episkopou H, Kyrtopoulos SA, et al
    Correction: Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian Cancer.
    PLoS One. 2021;16:e0256051.
    PubMed     Abstract available


  17. MCCORKLE JR, Gorski JW, Liu J, Riggs MB, et al
    Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.
    PLoS One. 2021;16:e0254205.
    PubMed     Abstract available


  18. JAREID M, Snapkov I, Holden M, Busund LR, et al
    The blood transcriptome prior to ovarian cancer diagnosis: A case-control study in the NOWAC postgenome cohort.
    PLoS One. 2021;16:e0256442.
    PubMed     Abstract available


  19. NAPOLI E, Bonsdorff TB, Jorstad IS, Bruland OS, et al
    Radon-220 diffusion from 224Ra-labeled calcium carbonate microparticles: Some implications for radiotherapeutic use.
    PLoS One. 2021;16:e0248133.
    PubMed     Abstract available


  20. HANNA DH, R Saad G
    Induction of mitochondria mediated apoptosis in human ovarian cancer cells by folic acid coated tin oxide nanoparticles.
    PLoS One. 2021;16:e0258115.
    PubMed     Abstract available


  21. HO PJ, Yeoh YS, Miao H, Lim SH, et al
    Cohort profile: The Singapore Breast Cancer Cohort (SGBCC), a multi-center breast cancer cohort for evaluation of phenotypic risk factors and genetic markers.
    PLoS One. 2021;16:e0250102.
    PubMed     Abstract available


  22. MIMOUN C, Paoletti X, Gaillard T, Crestani A, et al
    Using a new diagnostic tool to predict lymph node metastasis in advanced epithelial ovarian cancer leads to simple lymphadenectomy decision rules: A multicentre study from the FRANCOGYN group.
    PLoS One. 2021;16:e0258783.
    PubMed     Abstract available


  23. ANCHOORI RK, George L, Tseng SH, Lam B, et al
    Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors.
    PLoS One. 2021;16:e0256937.
    PubMed     Abstract available


  24. SAAVALAINEN L, Lassus H, But A, Gissler M, et al
    Incidence of extraovarian clear cell cancers in women with surgically diagnosed endometriosis: A cohort study.
    PLoS One. 2021;16:e0253270.
    PubMed     Abstract available


  25. KAUR P, Nagar S, Bhagwat M, Uddin M, et al
    Activated heme synthesis regulates glycolysis and oxidative metabolism in breast and ovarian cancer cells.
    PLoS One. 2021;16:e0260400.
    PubMed     Abstract available


    January 2020
  26. MIAO R, Badger TC, Groesch K, Diaz-Sylvester PL, et al
    Assessment of peritoneal microbial features and tumor marker levels as potential diagnostic tools for ovarian cancer.
    PLoS One. 2020;15:e0227707.
    PubMed     Abstract available


  27. STEINER B, Ferrucci LM, Mirabello L, Lan Q, et al
    Association between coffee drinking and telomere length in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    PLoS One. 2020;15:e0226972.
    PubMed     Abstract available


  28. AYYAGARI VN, Wang X, Diaz-Sylvester PL, Groesch K, et al
    Assessment of acyl-CoA cholesterol acyltransferase (ACAT-1) role in ovarian cancer progression-An in vitro study.
    PLoS One. 2020;15:e0228024.
    PubMed     Abstract available


  29. ARCHER S, Babb de Villiers C, Scheibl F, Carver T, et al
    Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study.
    PLoS One. 2020;15:e0229999.
    PubMed     Abstract available


  30. WEN H, Qian M, He J, Li M, et al
    Inhibiting of self-renewal, migration and invasion of ovarian cancer stem cells by blocking TGF-beta pathway.
    PLoS One. 2020;15:e0230230.
    PubMed     Abstract available


  31. WU W, Yu LH, Ma B, Xu MJ, et al
    Retraction: The Inhibitory Effect of Doxycycline on Cisplatin-Sensitive and -Resistant Epithelial Ovarian Cancer.
    PLoS One. 2020;15:e0231890.
    PubMed    


  32. LUBORSKY J, Barua A, Edassery S, Bahr JM, et al
    Inflammasome expression is higher in ovarian tumors than in normal ovary.
    PLoS One. 2020;15:e0227081.
    PubMed     Abstract available


  33. CHAMBERS LM, Esakov E, Braley C, AlHilli M, et al
    Use of Transabdominal Ultrasound for the detection of intra-peritoneal tumor engraftment and growth in mouse xenografts of epithelial ovarian cancer.
    PLoS One. 2020;15:e0228511.
    PubMed     Abstract available


  34. KIM KK, Turner R, Khazan N, Kodza A, et al
    Role of trypsin and protease-activated receptor-2 in ovarian cancer.
    PLoS One. 2020;15:e0232253.
    PubMed     Abstract available


  35. ZENG Y, Chen M, Ganesh S, Hu S, et al
    Clinicopathological and prognostic significance of caveolin-1 and ATG4C expression in the epithelial ovarian cancer.
    PLoS One. 2020;15:e0232235.
    PubMed     Abstract available


  36. PRICE JC, Azizi E, Naiche LA, Parvani JG, et al
    Notch3 signaling promotes tumor cell adhesion and progression in a murine epithelial ovarian cancer model.
    PLoS One. 2020;15:e0233962.
    PubMed     Abstract available


  37. OSTMEYER J, Lucas E, Christley S, Lea J, et al
    Biophysicochemical motifs in T cell receptor sequences as a potential biomarker for high-grade serous ovarian carcinoma.
    PLoS One. 2020;15:e0229569.
    PubMed     Abstract available


  38. ANTON C, Kleine RT, Mayerhoff E, Diz MDPE, et al
    Ten years of experience with endometrial cancer treatment in a single Brazilian institution: Patient characteristics and outcomes.
    PLoS One. 2020;15:e0229543.
    PubMed     Abstract available


  39. HAILU HE, Mondul AM, Rozek LS, Geleta T, et al
    Descriptive Epidemiology of breast and gynecological cancers among patients attending Saint Paul's Hospital Millennium Medical College, Ethiopia.
    PLoS One. 2020;15:e0230625.
    PubMed     Abstract available


  40. SOLDI R, Ghosh Halder T, Weston A, Thode T, et al
    The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
    PLoS One. 2020;15:e0235705.
    PubMed     Abstract available


  41. PYEON SY, Han GH, Ki KD, Lee KB, et al
    Effect of delayed palliative chemotherapy on survival of patients with recurrent ovarian cancer.
    PLoS One. 2020;15:e0236244.
    PubMed     Abstract available


  42. KELM NQ, Straughn AR, Kakar SS
    Withaferin A attenuates ovarian cancer-induced cardiac cachexia.
    PLoS One. 2020;15:e0236680.
    PubMed     Abstract available


  43. JOHNSON SC, Chakraborty S, Drosou A, Cunnea P, et al
    Inflammatory state of lymphatic vessels and miRNA profiles associated with relapse in ovarian cancer patients.
    PLoS One. 2020;15:e0230092.
    PubMed     Abstract available


  44. POLYMEROS K, Guttery DS, Hew R, Bishop R, et al
    Differences in the molecular profile of endometrial cancers from British White and British South Asian women.
    PLoS One. 2020;15:e0233900.
    PubMed     Abstract available


  45. MITTEMPERGHER L, Piskorz AM, Bosma AJ, Michaut M, et al
    Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene.
    PLoS One. 2020;15:e0235766.
    PubMed     Abstract available


  46. FADDA M, Chappuis PO, Katapodi MC, Pagani O, et al
    Physicians communicating with women at genetic risk of breast and ovarian cancer: Are we in the middle of the ford between contradictory messages and unshared decision making?
    PLoS One. 2020;15:e0240054.
    PubMed     Abstract available


  47. SAGLAM O, Tang Z, Tang G, Medeiros LJ, et al
    KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma.
    PLoS One. 2020;15:e0238477.
    PubMed     Abstract available


  48. SOPO M, Sallinen H, Hamalainen K, Kivela A, et al
    High expression of Tie-2 predicts poor prognosis in primary high grade serous ovarian cancer.
    PLoS One. 2020;15:e0241484.
    PubMed     Abstract available


  49. ESTERMANN M, Huang YL, Septiadi D, Ritz D, et al
    Patient-derived and artificial ascites have minor effects on MeT-5A mesothelial cells and do not facilitate ovarian cancer cell adhesion.
    PLoS One. 2020;15:e0241500.
    PubMed     Abstract available


  50. SIEBENKAS C, Chiappinelli KB, Guzzetta AA, Sharma A, et al
    Correction: Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells.
    PLoS One. 2020;15:e0243944.
    PubMed     Abstract available


  51. LEANDERSSON P, Akesson A, Hedenfalk I, Malander S, et al
    A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    PLoS One. 2020;15:e0240418.
    PubMed     Abstract available


  52. WANG Y, Tao VL, Shin CY, Salamanca C, et al
    Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line.
    PLoS One. 2020;15:e0240412.
    PubMed     Abstract available


  53. PATRA B, Lateef MA, Brodeur MN, Fleury H, et al
    Carboplatin sensitivity in epithelial ovarian cancer cell lines: The impact of model systems.
    PLoS One. 2020;15:e0244549.
    PubMed     Abstract available


  54. BATES M, Spillane CD, Gallagher MF, McCann A, et al
    The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.
    PLoS One. 2020;15:e0243715.
    PubMed     Abstract available


    January 2019
  55. FRAGOSO-ONTIVEROS V, Velazquez-Aragon JA, Nunez-Martinez PM, de la Luz Mejia-Aguayo M, et al
    Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients.
    PLoS One. 2019;14:e0222709.
    PubMed     Abstract available


  56. GORZELITZ J, Costanzo ES, Spencer RJ, Rumble M, et al
    Longitudinal assessment of post-surgical physical activity in endometrial and ovarian cancer patients.
    PLoS One. 2019;14:e0223791.
    PubMed     Abstract available


  57. AMIT A, Sabo E, Movsas A, Efrat-Tamam Y, et al
    Can morphometric analysis of the fallopian tube fimbria predict the presence of uterine papillary serous carcinoma (UPSC)?
    PLoS One. 2019;14:e0211329.
    PubMed     Abstract available


  58. DURAN GE, Sikic BI
    The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance.
    PLoS One. 2019;14:e0210879.
    PubMed     Abstract available


  59. MRKVICOVA A, Chmelarova M, Peterova E, Havelek R, et al
    The effect of sodium butyrate and cisplatin on expression of EMT markers.
    PLoS One. 2019;14:e0210889.
    PubMed     Abstract available


  60. TORRES D, Hou X, Bale L, Heinzen EP, et al
    Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A.
    PLoS One. 2019;14:e0224564.
    PubMed     Abstract available


  61. OLIVEIRA DNP, Carlsen AL, Heegaard NHH, Prahm KP, et al
    Diagnostic plasma miRNA-profiles for ovarian cancer in patients with pelvic mass.
    PLoS One. 2019;14:e0225249.
    PubMed     Abstract available


  62. WANG F, Chen X, Yuan D, Yi Y, et al
    Golgi reassembly and stacking protein 65 downregulation is required for the anti-cancer effect of dihydromyricetin on human ovarian cancer cells.
    PLoS One. 2019;14:e0225450.
    PubMed     Abstract available


  63. WAMBECKE A, Laurent-Issartel C, Leroy-Dudal J, Giffard F, et al
    Evaluation of the potential of a new ribavirin analog impairing the dissemination of ovarian cancer cells.
    PLoS One. 2019;14:e0225860.
    PubMed     Abstract available


  64. ZHAO Y, Mehta M, Walton A, Talsania K, et al
    Robustness of RNA sequencing on older formalin-fixed paraffin-embedded tissue from high-grade ovarian serous adenocarcinomas.
    PLoS One. 2019;14:e0216050.
    PubMed     Abstract available


  65. CHE L, Yang X, Ge C, El-Amouri SS, et al
    Loss of BRUCE reduces cellular energy level and induces autophagy by driving activation of the AMPK-ULK1 autophagic initiating axis.
    PLoS One. 2019;14:e0216553.
    PubMed     Abstract available


  66. MARTINEZ-MAS J, Bueno-Crespo A, Khazendar S, Remezal-Solano M, et al
    Evaluation of machine learning methods with Fourier Transform features for classifying ovarian tumors based on ultrasound images.
    PLoS One. 2019;14:e0219388.
    PubMed     Abstract available


  67. KIM B, Won D, Lee ST, Choi JR, et al
    Somatic mosaic truncating mutations of PPM1D in blood can result from expansion of a mutant clone under selective pressure of chemotherapy.
    PLoS One. 2019;14:e0217521.
    PubMed     Abstract available


  68. ZEH N, Schneider H, Mathias S, Raab N, et al
    Human CAP cells represent a novel source for functional, miRNA-loaded exosome production.
    PLoS One. 2019;14:e0221679.
    PubMed     Abstract available


  69. BISHOP MR, Huskey ALW, Hetzel J, Merner ND, et al
    A research-based gene panel to investigate breast, ovarian and prostate cancer genetic risk.
    PLoS One. 2019;14:e0220929.
    PubMed     Abstract available


  70. ANDRADE DAP, da Silva VD, Matsushita GM, de Lima MA, et al
    Squamous differentiation portends poor prognosis in low and intermediate-risk endometrioid endometrial cancer.
    PLoS One. 2019;14:e0220086.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: